Increased fluid intake may be needed if experiencing nausea, vomiting, or diarrhea, as dehydration frequently underlies headaches in patients taking these medications
A review of 30 randomized controlled trials that included 1,736 people with type 2 diabetes or non-alcoholic fatty liver disease found that treatment with GLP-1 agonists significantly reduced both visceral and liver fat
Br J Clin Pharmacol (2019) 85:271420
Acknowledgments The authors would like to thank SHRM, and particularly SHRM Tennessee and SHRM Austin, as well as the Midwest Business Group on Health, the NC Business Coalition on Health, and The Alliance for their assistance in organizing the focus groups
2: Reduction in Certain Diseases Recent clinical trial results suggest that the health impacts of GLP-1RAs go beyond weight loss, with the drug leading to a reduction in various diseases, such as cardiovascular disease or slowing down the progression of some illnesses such as chronic kidney disease
This includes your weight history, body mass index (BMI), any related health conditions, the medications youre currently taking, and any side effects you may have experienced in the past
